For nearly eight years, New Jersey-based Par Pharmaceutical made millions of dollars by aggressively pushing Megace ES as a weight-gain drug for patients in nursing homes and other long-term care facilities.
Subscribe to the AARP Health Newsletter … Back to Article
Topic Alerts
You can get weekly email alerts on the topics below. Just click “Follow.”
Manage AlertsProcessing
Please wait...











Tell Us WhatYou Think
Please leave your comment below.
You must be signed in to comment.
Sign In | Register